Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $2.89 in the prior trading day, Protalix BioTherapeutics Inc (AMEX: PLX) closed at $1.72, down -40.48%. In other words, the price has decreased by -$40.48 from its previous closing price. On the day, 5.94 million shares were traded.
Ratios:
Our goal is to gain a better understanding of PLX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 2.49. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Valuation Measures:
As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.95, and their Forward P/E ratio for the next fiscal year is 2.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.29 while its Price-to-Book (P/B) ratio in mrq is 2.97.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $3.10, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is -32.06%, while the 200-Day Moving Average is calculated to be -3.74%.
Shares Statistics:
A total of 78.13M shares are outstanding, with a floating share count of 73.73M. Insiders hold about 7.28% of the company’s shares, while institutions hold 6.99% stake in the company.
